Evidence map›Paper›PMID 40589650›Full record

ArticleFrontiers in psychiatry2025

Longitudinal recovery and self-efficacy in first-episode schizophrenia: insights from a 10-year follow-up study.

Anne-Kari Torgalsbøen, Christine Mohn, Frank Larøi, Nikolai Czajkowski

Abstract read
In one paragraph

Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Anne-Kari TorgalsbøenDepartment of Psychology University of Oslo, Oslo, Norway.
Christine MohnNational Centre for Suicide Prevention and Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Frank LarøiDepartment of Psychology University of Oslo, Oslo, Norway.
Nikolai CzajkowskiDepartment of Psychology University of Oslo, Oslo, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Research on clinical recovery rates in first-episode schizophrenia has yielded inconsistent results due to varying definitions of recovery and methodological differences. The longitudinal trajectory of recovery-whether rates improve, decline, or remain stable-remains unclear. Schizophrenia significantly impacts young lives, making it crucial to examine self-efficacy, the belief in one's ability to manage adversity, and its relationship with clinical recovery. Methods: The Oslo Schizophrenia Recovery study`s repeated assessment design, including twelve clinical evaluations over ten years, is ideal for studying longitudinal recovery. Self-efficacy was measured using the General Perceived Self-Efficacy scale, with data analyzed through linear multilevel models. Twenty-eight well-defined first-episode schizophrenia patients were assessed yearly, using a strict recovery definition (two years of full symptom remission and adequate social/role functioning), with 79% of patients retained from baseline. Results: Recovery rates improved and remained stable, suggesting better outcomes than previously reported. Of the participants, 50% achieved clinical recovery. Recovered individuals showed a sharp increase in self-efficacy within the first year, while non-recovered patients exhibited gradual improvement. The interaction between recovery status and time revealed distinct self-efficacy trajectories, particularly in the first post-onset year. Conclusions: A significant proportion of first-episode schizophrenia patients can achieve clinical recovery. While these positive outcomes are noteworthy, it is important to recognize that recovery paths can vary widely among individuals. Since people with schizophrenia are concerned about their chances of recovery, the results must be shared with patients and their families. While the causal relationship between self-efficacy and recovery remains unclear, they likely influence each other.

Indexed as

clinical recoverycoursefirst-episode schizophrenialongitudinaloutcomeprognosisself-efficacy

Identifiers

PMID40589650
PMCPMC12207743

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.